PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a study demonstrating the capabilities…
PhoreMost demonstrates new approach to rationalize molecular glue drug discovery
